Status: Not yet recruiting
Asciminib Frontline Risk Adapted
This is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD. Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib. The study will be conducted in Germany.
Participants needed: 200
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Prof. Dr. med. Andreas HochhausUpdated: Sep 4, 2026Locations: 1
Eligibility criteria
Signed informed consent must be obtained prior to participation in the trial [+15]
Previous treatment for CML or any other anticancer agents including chemotherapy... [+26]